Literature DB >> 10072192

Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats.

J Emami1, F M Pasutto, J R Mercer, F Jamali.   

Abstract

To elucidate the mechanism by which hydroxychloroquine (HCQ) affects glucose metabolism, the effect of this drug and its enantiomers on insulin metabolism was studied using the cytosolic fraction of liver homogenates from healthy and diabetic rats. Eadie-Hofstee plots were monophasic suggesting that only a one-component enzyme system is involved in insulin degradation in the fraction used. Reaction velocity (V) vs substrate concentration plots were consistent with a Vmax model. HCQ caused a significant reduction in Vmax and Vmax/Km values in both healthy (Vmax, 3.63 +/- 0.46 vs 1.97 +/- 0.13, ng/min/mg; protein P < 0.001; and Vmax/Km 0.265 +/- 0.015 vs 0.112 +/- 0.004, ml/min/g protein) and diabetic rats (Vmax, 0.718 +/- 0.06 vs 0.360 +/- 0.024, ng/min/mg protein; and Vmax/Km, 0.05 +/- 0.002 vs 0.023 +/- 0.001, ml/min/g protein). Significant reduction in the V was observed in the presence of racemic (rac)-, R-, or S-HCQ. Ranking of the inhibitory potency was HCQ > S = R except at highest examined concentration (20 mg/mL) which was HCQ > S > R. In conclusion, the effect of HCQ on insulin degradation appears to be, in part, through inhibition of cytosolic insulin metabolizing enzyme. The effect is not stereoselective except at high concentrations. The R- and S-HCQ may have synergistic effects on inhibition of insulin degradation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072192     DOI: 10.1016/s0024-3205(98)00568-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

1.  Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Authors:  Laura R Rekedal; Elena Massarotti; Rajesh Garg; Radhika Bhatia; Timothy Gleeson; Bing Lu; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2010-12

Review 2.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 3.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.

Authors:  Mirella P Hage; Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-08       Impact factor: 3.565

Review 4.  Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.

Authors:  Ahmed El-Solia; Khalid Al-Otaibi; Abdullah K Ai-Hwiesh
Journal:  BMJ Case Rep       Date:  2018-04-18

5.  Hydroxychloroquine as a glucose lowering drug.

Authors:  Elizabeth Martha Winter; Anita Schrander-van der Meer; Carmen Eustatia-Rutten; Martien Janssen
Journal:  BMJ Case Rep       Date:  2011-10-28

6.  Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats.

Authors:  Anil Pareek; P G Yeole; C R Tenpe; Nitin Chandurkar; Ravikiran Payghan
Journal:  Indian J Pharmacol       Date:  2009-06       Impact factor: 1.200

Review 7.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

Authors:  Afshan Siddiq; Rafeeq Alam Khan; Sadia Ghousia Baig
Journal:  J Pharm Bioallied Sci       Date:  2011-04

Review 9.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

Review 10.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.